Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer’s Intervention by 4.5 Years
Elisabeth Thijssen, PhD, Chief Scientific Officer of Neurogen Biomarking.
What You Should Know:
– Advancements in accelerating early Alzheimer’s disease (AD) screening and access to care, proven from three diverse community pilot initiatives, were presented today…
Continue Reading